Showing results (491-500 of 509) with videos related to
Sort By:
Pageof 51
Journal of Medicinal Chemistry|September 25, 2009
Discovery of azetidinyl ketolides for the treatment of susceptible and multidrug resistant community-acquired respiratory tract infectionsThomas V Magee, Sharon L Ripp, Bryan Li, et al.The Journal of Clinical Investigation|September 9, 2025
Recessive TMEM167A variants cause neonatal diabetes, microcephaly, and epilepsy syndromeEnrico Virgilio, Sylvia Tielens, Georgia Bonfield, et al.Cell|April 14, 2021
Reducing acetylated tau is neuroprotective in brain injuryMin-Kyoo Shin, Edwin Vázquez-Rosa, Yeojung Koh, et al.Acta Neuropathologica|May 25, 2026
Neocortical tau burden determines the degree of cognitive impairment in individuals with Braak stage V neurofibrillary degenerationTimothy E Richardson, Jonathan Cherry, Shrishtee Kandoi, et al.Neuron|July 19, 2025
Accelerating biomedical discoveries in brain health through transformative neuropathology of aging and neurodegenerationMelissa E Murray, Colin Smith, Vilas Menon, et al.Proceedings of the National Academy of Sciences of the United States of America|May 21, 2025
Inhibiting 15-PGDH blocks blood-brain barrier deterioration and protects mice from Alzheimer's disease and traumatic brain injuryYeojung Koh, Edwin Vázquez-Rosa, Farrah Gao, et al.Acta Neuropathologica|December 13, 2022
LATE-NC staging in routine neuropathologic diagnosis: an updatePeter T Nelson, Edward B Lee, Matthew D Cykowski, et al.Acta Neuropathologica|June 13, 2022
Frequency of LATE neuropathologic change across the spectrum of Alzheimer's disease neuropathology: combined data from 13 community-based or population-based autopsy cohortsPeter T Nelson, Carol Brayne, Margaret E Flanagan, et al.Journal of Neuropathology and Experimental Neurology|December 28, 2020
Early Selective Vulnerability of the CA2 Hippocampal Subfield in Primary Age-Related TauopathyJamie M Walker, Timothy E Richardson, Kurt Farrell, et al.Science (New York, N.Y.)|November 1, 2003
Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitorPaul S Changelian, Mark E Flanagan, Douglas J Ball, et al.Pageof 51